Compare Inovio Pharmaceuticals Inc (INO) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Kaltura Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.11 (market cap $112.19M), while Kaltura Inc trades at $1.31 (market cap $199.08M). The key difference: Kaltura Inc is the larger of the two by market cap, and Kaltura Inc is more actively traded (175,927 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Kaltura Inc for 21 Days on average.
| INO | KLTR | |
|---|---|---|
Market Cap | $112.19M | $199.08M |
Volume | 3,201,278 | 175,927 |
Sector | Health | Technology |
52-Week High | $2.65 | $1.89 |
52-Week Low | $0.66 | $1.08 |
Typical Hold Time | 43 Days | 21 Days |
Enterprise Value | $83.51M | $211.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
KLTR trades at $1.315, down 1.13% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals, with revenue stable around $181M in 2025 and a narrowing net loss of -$12.07M, though profitability remains negative. Recent news highlights AI-driven innovations and industry recognition, including a Gartner leadership mention in August 2026. Analyst sentiment is mixed with a 44% buy rating.
The outlook hinges on KLTR's ability to monetize its AI and video platform investments to achieve sustained profitability. Key risks include high debt levels, persistent negative margins, and competitive pressures. Upside potential exists if the company converts its technological accolades into revenue growth and positive earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
